TCR-engineered T cells: A model of inducible TCR expression to dissect the interrelationship between two TCRs

被引:13
|
作者
Reuss, Simone [1 ]
Sebestyen, Zsolt [2 ]
Heinz, Niels [3 ]
Loew, Rainer [4 ]
Baum, Christopher [3 ]
Debets, Reno [2 ]
Uckert, Wolfgang [1 ,5 ]
机构
[1] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany
[2] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Hannover Med Sch, Hannover, Germany
[4] Eufets GmbH, Idar Oberstein, Germany
[5] Humboldt Univ, Inst Biol, D-10099 Berlin, Germany
关键词
RECEPTOR GENE-THERAPY; ENHANCED ANTITUMOR-ACTIVITY; CANCER REGRESSION; SINGLE-CHAIN; LYMPHOCYTES; ALPHA; BETA; ANTIGEN; SPECIFICITY; RECOGNITION;
D O I
10.1002/eji.201343591
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
TCR gene modified T cells for adoptive therapy simultaneously express the Tg TCR and the endogenous TCR, which might lead to mispaired TCRs with harmful unknown specificity and to a reduced function of TCR-Tg T cells. We generated dual TCR T cells in two settings in which either TCR was constitutively expressed by a retroviral promoter while the second TCR expression was regulable by a Tet-on system. Constitutively expressed TCR molecules were reduced on the cell surface depending on the induced TCR expression leading to strongly hampered function. Besides that, using fluorescence resonance energy transfer we detected mispaired TCR dimers and different pairing behaviors of individual TCR chains with a mutual influence on TCR chain expression. The loss of function and mispairing could not be avoided by changing the TCR expression level or by introduction of an additional cysteine bridge. However, in polyclonal T cells, optimized TCR formats (cysteineization, codon optimization) enhanced correct pairing and function. We conclude from our data that (i) the level of mispairing depends on the individual TCRs and is not reduced by increasing the level of one TCR, and (ii) modifications (cysteineization, codon optimization) improve correct pairing but do not completely exclude mispairing (cysteineization). © 2013 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
引用
收藏
页码:265 / 274
页数:10
相关论文
共 50 条
  • [31] Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells
    San Miguel, Jesus F.
    Paiva, Bruno
    Lasarte, Juan-Jose
    CANCER CELL, 2015, 28 (03) : 281 - 283
  • [32] Mass-spectrometry-guided target selection and TCR profiling: towards the development of safer TCR-engineered T cell therapies
    Demberg, Thorsten
    Kalra, Mamta
    Alten, Leonie
    Alpert, Amir
    Bunk, Sebastian
    Fritsche, Jens
    Schoor, Oliver
    Maurer, Dominik
    Mohammed, Ali
    Bulliard, Yannick
    Singh, Harpreet
    Reinhardt, Carsten
    Weinschenk, Toni
    Walter, Steffen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [33] Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
    Pang, Zhi
    Lu, Man-man
    Zhang, Yu
    Gao, Yuan
    Bai, Jin-jin
    Gu, Jian-ying
    Xie, Lu
    Wu, Wei-zhong
    BIOMARKER RESEARCH, 2023, 11 (01)
  • [34] Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
    Zhi Pang
    Man-man Lu
    Yu Zhang
    Yuan Gao
    Jin-jin Bai
    Jian-ying Gu
    Lu Xie
    Wei-zhong Wu
    Biomarker Research, 11
  • [35] The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
    Campillo-Davo, Diana
    Flumens, Donovan
    Lion, Eva
    CELLS, 2020, 9 (07)
  • [36] Transcriptional signatures in human melanoma epitope MART-127-35 specific TCR-engineered T cells
    Singh, Prashant
    Chakraborty, Nitya G.
    Farooq, Umar
    Hegde, Upendra P.
    Everson, Richard
    Dorsky, David I.
    Mukherji, Bijay
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Two clinical trials of adoptive transfer of TCR-engineered T cells specific to MAGE-A4 and NY-ESO-1
    Kageyama, Shinichi
    Ishihara, Mikiya
    Kitano, Shigehisa
    Miyahara, Yoshihiro
    Kato, Hidefumi
    Mishima, Hideyuki
    Yamamoto, Noboru
    Iwase, Hiroaki
    Hattori, Hiroyoshi
    Funakoshi, Takeshi
    Kojima, Takashi
    Watanabe, Takashi
    Shiku, Hiroshi
    CANCER SCIENCE, 2018, 109 : 534 - 534
  • [38] Enhancing Efficacy of TCR-engineered CD4+ T Cells Via Coexpression of CD8α
    Anderson, Victoria E.
    Brilha, Sara S.
    Weber, Anika M.
    Pachnio, Annette
    Wiedermann, Guy E.
    Dauleh, Sumaya
    Ahmed, Tina
    Pope, George R.
    Quinn, Laura L.
    Docta, Roslin Y.
    Quattrini, Adriano
    Masters, Siobhan
    Cartwright, Neil
    Viswanathan, Preetha
    Melchiori, Luca
    Rice, Louise V.
    Sevko, Alexandra
    Gueguen, Claire
    Saini, Manoj
    Tavano, Barbara
    Abbott, Rachel J. M.
    Silk, Jonathan D.
    Laugel, Bruno
    Sanderson, Joseph P.
    Gerry, Andrew B.
    JOURNAL OF IMMUNOTHERAPY, 2023, 46 (04) : 132 - 144
  • [39] Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia
    Campillo-Davo, Diana
    Anguille, Sebastien
    Lion, Eva
    CANCERS, 2021, 13 (18)
  • [40] TCR engineered T cells for solid tumor immunotherapy
    Zhang, Yikai
    Liu, Zhipeng
    Wei, Wei
    Li, Yangqiu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)